Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.00 -1.1%	$7.97	$6.10 ▼ $28.67	$554.03M	1.41	398,061 shs	214,585 shs
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.84 million shs	N/A
ICPT Intercept Pharmaceuticals	$19.00	$18.88	$8.82 ▼ $21.86	$794.77M	0.88	1.36 million shs	N/A
SNDX Syndax Pharmaceuticals	$9.59 -2.3%	$10.05	$8.58 ▼ $25.07	$825.19M	0.7	1.86 million shs	1.51 million shs
VBIV VBI Vaccines		$0.23	$0.06 ▼ $1.35	$1.87M	2.18	3.66 million shs	29.90 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	+7.74%	-7.94%	+19.40%	-61.92%
CMRX Chimerix	0.00%	0.00%	0.00%	+0.23%	+918.36%
ICPT Intercept Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SNDX Syndax Pharmaceuticals	0.00%	+3.39%	-10.12%	-14.07%	-57.73%
VBIV VBI Vaccines	0.00%	0.00%	0.00%	0.00%	-91.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.7238 of 5 stars	4.4	2.0	0.0	0.0	2.3	4.2	0.6
CMRX Chimerix	0.5486 of 5 stars	1.0	0.0	0.0	4.1	0.0	1.7	0.6
ICPT Intercept Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	3.1775 of 5 stars	3.5	0.0	0.0	4.4	2.7	0.0	0.0
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	212.50% Upside
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
ICPT Intercept Pharmaceuticals	0.00	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.30	257.66% Upside
VBIV VBI Vaccines	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CMRX, BCYC, VBIV, ICPT, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$25.72M	21.54	N/A	N/A	$11.48 per share	0.70
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
ICPT Intercept Pharmaceuticals	$285.71M	2.78	N/A	N/A	$1.72 per share	11.05
SNDX Syndax Pharmaceuticals	$23.68M	34.85	N/A	N/A	$3.38 per share	2.84
VBIV VBI Vaccines	$9.41M	0.00	N/A	N/A	$0.32 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
ICPT Intercept Pharmaceuticals	$221.82M	-$1.48	N/A	9.84	N/A	-19.39%	-77.48%	-11.99%	N/A
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)
VBIV VBI Vaccines	-$92.84M	N/A	0.00	N/A	N/A	-881.79%	-525.42%	-45.87%	N/A

Latest CMRX, BCYC, VBIV, ICPT, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	N/A	N/A	N/A	$9.43 million	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
ICPT Intercept Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
CMRX Chimerix	N/A	6.33	6.33
ICPT Intercept Pharmaceuticals	3.12	4.22	2.52
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75
VBIV VBI Vaccines	N/A	0.34	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
CMRX Chimerix	45.42%
ICPT Intercept Pharmaceuticals	83.81%
SNDX Syndax Pharmaceuticals	N/A
VBIV VBI Vaccines	12.26%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
CMRX Chimerix	13.10%
ICPT Intercept Pharmaceuticals	6.20%
SNDX Syndax Pharmaceuticals	4.10%
VBIV VBI Vaccines	10.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
ICPT Intercept Pharmaceuticals	341	41.83 million	39.19 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable
VBIV VBI Vaccines	22	28.68 million	25.71 million	Optionable

CMRX, BCYC, VBIV, ICPT, and SNDX Headlines

Recent News About These Companies

Brii Biosciences buying VBI Vaccine’s hepatitis B therapy

January 24, 2025 | ncbiotech.orgN

VBI Vaccines Restructures and Acquired by K2 VBI Trust

January 3, 2025 | tipranks.com

VBI recalls PreHevbrio and winds down operations

November 20, 2024 | thepharmaletter.comT

Hepatitis B Vaccine PreHevbrio Recalled Due to Company Bankruptcy

November 19, 2024 | empr.comE

VBI Vaccines recalls hepatitis B shot as it winds down operations

November 18, 2024 | fiercepharma.comF

VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations

November 15, 2024 | businesswire.com

VBI Vaccines Inc. (VBIV): Unpacking the 80% Stock Surge During Restructuring

August 6, 2024 | bovnews.comB

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

August 6, 2024 | investorplace.com

VBI Vaccines to be delisted from Nasdaq following restructuring

August 4, 2024 | investing.com

VBI Vaccines Provides an Update on its Restructuring Proceedings

August 3, 2024 | finance.yahoo.com

VBI Vaccines secures court protection for restructuring

August 1, 2024 | investing.com

VBI craters as investors react to Hep B vaccine data

July 31, 2024 | pharmaphorum.comP

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

July 30, 2024 | stockhouse.com

VBI Vaccines Announces Results of Annual General Meeting

June 25, 2024 | businesswire.com

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

May 29, 2024 | businesswire.com

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

May 22, 2024 | businesswire.com

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

May 15, 2024 | investorplace.com

VBI Vaccines Reports First Quarter 2024 Financial Results

May 15, 2024 | businesswire.com

VBI Vaccines expands partnership with Canadian government on a vaccine platform

May 13, 2024 | plant.caP

VBI Vaccines Reports Full Year 2023 Financial Results

April 16, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMRX, BCYC, VBIV, ICPT, and SNDX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.00 -0.09 (-1.11%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$7.50 -0.51 (-6.31%)

As of 07/11/2025 04:29 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)

As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Intercept Pharmaceuticals NASDAQ:ICPT

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Syndax Pharmaceuticals NASDAQ:SNDX

$9.59 -0.23 (-2.34%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.59 0.00 (-0.05%)

As of 07/11/2025 05:51 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time